Literature DB >> 1657424

Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.

J L Fischel1, P Formento, M Berlion, J Berille, J Gioanni, J P Bizzari, G Milano.   

Abstract

The present study was designed to analyse the cytotoxic effects of the combination of fotemustine with 5-fluorouracil (5-FU) plus folinic acid (FA). Two human tumor cell lines were used; one line was derived from colon cancer (WIDR) and the other, from a non-small-cell lung cancer (CAL 12). Cytotoxic effects were assessed using the MTT (tetrazolium bromide) semi-automated test in 96-well incubation plates. The effects of various drug combinations were evaluated by the isobologram method. The drug combinations tested included fotemustine concentrations of 20, 30, 40, 50 and 70 micrograms/ml, 5-FU concentrations of 5, 15 and 30 micrograms/ml, and a constant FA concentration of 10(-5) M. A total of 180 different experimental conditions were tested. When cells were exposed to fotemustine prior to treatment with 5-FU, the final cytotoxic effects on both cell lines were additive or synergistic in the majority of cases (P less than 0.001). The 5-FU concentration was a determinant factor that modified the effects of the drug combination from antagonism (at low 5-FU concentrations) to synergism (high 5-FU concentrations; P less than 0.001). The addition of FA (10(-5) M) resulted in a significant shift towards synergistic associations in both cell lines. Administration of 5-FU prior to treatment with fotemustine caused marked antagonism, which 10(-5) M FA could not significantly shift towards simple additivity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657424     DOI: 10.1007/bf00685821

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

Review 1.  The metabolic basis for combination chemotherapy.

Authors:  L E Damon; E C Cadman
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

2.  Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil.

Authors:  J R Bertino; W L Sawicki; C A Lindquist; V S Gupta
Journal:  Cancer Res       Date:  1977-01       Impact factor: 12.701

Review 3.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

Review 4.  Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

Authors:  F M Schabel; D P Griswold; T H Corbett; W R Laster
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

5.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.

Authors:  C J van Groeningen; H M Pinedo; J Heddes; R M Kok; A P de Jong; E Wattel; G J Peters; J Lankelma
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

6.  Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.

Authors:  D Khayat; F Lokiec; J P Bizzari; M Weil; L Meeus; M Sellami; J Rouesse; P Banzet; C Jacquillat
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

7.  Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.

Authors:  C Benz; T Tillis; E Tattelman; E Cadman
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

8.  In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.

Authors:  J L Fischel; P Formento; M C Etienne; J Gioanni; M Frenay; P Deloffre; J P Bizzari; G Milano
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 9.  Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.

Authors:  S G Arbuck
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

10.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.

Authors:  P R Twentyman; M Luscombe
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.